TORONTO, Ontario and HAIFA, Israel, June 25, 2026 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome-based regenerative therapies, is pleased to announce today that its wholly owned U.S. subsidiary, Exo-Top Inc. (“Exo-Top”), has entered into a binding memorandum of understanding (the “MOU”) setting out the principal commercial terms for a proposed definitive distribution agreement (the “Definitive Agreement”) with ExoLyra LLC, which operates as an arm’s length third party (“ExoLyra”).
The commercial terms outlined in the MOU, including territorial exclusivity, upfront exclusivity fees, minimum purchase commitments, funded market-entry obligations, regulatory responsibilities, and potential regional expansion rights, are intended to be incorporated into the Definitive Agreement, which the parties intend to execute within forty-five (45) calendar days. If completed, the Definitive Agreement will provide Exo-Top with its first structured commercial foothold for naïve MSC-derived exosome products.